Interleukin-6 (IL-6) inhibitors as therapeutic agents for coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis

INTRODUCTION: Preliminary studies showed that coronavirus disease 2019 (COVID-19) disrupts body immune system, including dysregulation of cytokine interleukin-6 (IL-6). IL-6 inhibitors agents have been used as treatment options for COVID-19, yet their benefit as therapeutic agents remains unclear. O...

Descripción completa

Detalles Bibliográficos
Autores principales: Pinzon, Rizaldy Taslim, Wijaya, Vincent Ongko, Buana, Ranbebasa Bijak
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences. 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8204364/
https://www.ncbi.nlm.nih.gov/pubmed/34153723
http://dx.doi.org/10.1016/j.jiph.2021.06.004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8204364/
https://www.ncbi.nlm.nih.gov/pubmed/34153723
http://dx.doi.org/10.1016/j.jiph.2021.06.004

Ejemplares similares